Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12343975 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL26384544 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL3822584 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL11608428 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL28987822 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL3823100 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL20651164 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL13140041 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL28987842 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL26849768 | 0.78 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099466-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2026-05-15 | — | — | WO | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| CN-114835656-A | 1,3, 4-oxadiazole ethyl acetate and synthesis method thereof | 天津中医药大学 | 2022-08-02 | — | — | CN | disclosed |
| US-20210277030-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| CN-108473426-B | Cyclic amine derivative and medical use thereof | 东丽株式会社 | 2021-09-07 | — | — | CN | disclosed |
| US-11053262-B2 | Heterocyclic amide compounds having RORyT inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-06 | — | — | US | disclosed |
| US-10881649-B2 | Therapeutic agent or preventive agent for alopecia areata | TORAY INDUSTRIES, INC. (JP) | 2021-01-05 | — | — | US | disclosed |
| US-10881649-B2 | Therapeutic agent or preventive agent for alopecia areata | TORAY INDUSTRIES, INC. (JP) | 2021-01-05 | — | — | US | disclosed |
| EP-3746079-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-12-09 | — | — | EP | disclosed |
| WO-2017131156-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 東レ株式会社 | 2017-08-03 | — | — | WO | disclosed |
| US-20170107240-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3018123-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1336/4885CA12 3624/4885CA1 2463/4885 |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1710/4885CA12 2542/4885CA1 1169/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | SMN1; SMN2 4127/4885CA12 1747/4885CA1 681/4885 |
| US-20170107240-A1 | AMIDE COMPOUND | RORB, RORC, RORA | SMN1; SMN2 4136/4885CA12 1061/4885CA1 311/4885 |
| US-10881649-B2 | Therapeutic agent or preventive agent for alopecia areata | RORA, RORB, RORC | SMN1; SMN2 4834/4885CA12 647/4885CA1 599/4885 |
| US-20210277030-A1 | AMIDE COMPOUND | RORB, RORC, RORA | SMN1; SMN2 4136/4885CA12 1061/4885CA1 311/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1710/4885CA12 2542/4885CA1 1169/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | SMN1; SMN2 3917/4885CA12 852/4885CA1 162/4885 |
| US-11053262-B2 | Heterocyclic amide compounds having RORyT inhibitory action | RORC, RORB, RORA | SMN1; SMN2 4241/4885CA12 527/4885CA1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.